Table 2 Relevant features of functionally studied cohorts.

From: Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection

 

Asymptomatic/mild n = 8

Moderate/severe n = 11

Symptoms n (%)

Asymptomatic n = 2 (10.5)

Mild n = 6 (31.6)

Moderate n = 8 (42.1)

Severe n = 3 (15.8)

Mean DPI/DPSI ± SDa

238.8 ± 118.7

189.8 ± 119.2

Median age (IQR)

Mean age ± SD

68 (53.7-70.5)

59.2 ± 18.4

59 (52-66)

58.1 ± 12.5

Female n (%)

5 (62.5)

6 (54.5)

Male n (%)

3 (37.5)

5 (45.5)

Mean DPV1 ± SD1

56.6 ± 13.2

50.9 ± 14.6

Pfizer-BioNTech n (%)

8 (100)

10 (90.9)

Moderna n (%)

0

1 (9.1)

Mean DPV2 ± SD1

71.8 ± 31.1

78.9 ± 21.3

Pfizer-BioNTech n (%)

7 (87.5)

5 (45.5)

Moderna n (%)

1 (12.5)

6 (54.5)

Mean days between vaccination ± SD

76 ± 16.5

64.7 ± 23.2

  1. aDays post infection or days post symptoms onset at collection (DPI/DPSO); days post first vaccination (DPV1); days post second vaccination (DPV2).
Back to article page